Cargando…
Enhanced antitumor immune responses via a new agent [(131)I]-labeled dual-target immunosuppressant
ABSTRACT: Radionuclides theranostic are ideal “partners” for bispecific antibodies to explore the immune response of patients and synergistic treatment. A bispecific single-domain antibody-Fc fusion protein, KN046, exhibits a good treatment effect by binding to programmed cell death-ligand 1 (PD-L1)...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816240/ https://www.ncbi.nlm.nih.gov/pubmed/36242616 http://dx.doi.org/10.1007/s00259-022-05986-4 |